AstraZeneca's COVID prevention drug application gets EU fast-track assessment
Adds details and background in paragraphs 3-6
July 1 (Reuters) -AstraZeneca AZN.L said on Monday that the European Uniondrug regulator has accepted a market authorisation application for its investigational COVID-19 prevention drug, sipavibart, for an accelerated assessment.
The submission was based on positive data from a late-stage trial that showed the drug reduced the risk of infection in patients with weaker immunity.
"The EMA's (European Medicines Agency) Committeefor Medicinal Products for Human Use(CHMP) granted sipavibart accelerated assessment as it was deemed of major interest for public health and therapeutic innovation," the Anglo-Swedish drugmaker said.
An accelerated assessment aims to speed up the EMA's review of a market authorisation application.
AstraZeneca acquired sipavibart from RQ Bio in May 2022.
The drugmaker earlier this year withdrew its COVID-19 vaccine, one of the first and most widely used, due to "surplus of available updated vaccines" since the pandemic.
Reporting by Yadarisa Shabong in Bengaluru; Editing by Sonia Cheema
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
